European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

D M Conti; V Backer; W Fokkens; P Gevaert; A Peters; G K Scadding; I Pavord; S Lau; M Wechsler; X Bertels; G Liva; M Doulaptsi; E Prokopakis; P W Hellings

doi:10.3389/falgy.2024.1517122

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

Front Allergy. 2024 Dec 12:5:1517122. doi: 10.3389/falgy.2024.1517122. eCollection 2024.

Authors

D M Conti^{1

2

3}, V Backer⁴, W Fokkens⁵, P Gevaert⁶, A Peters⁷, G K Scadding^{8

9}, I Pavord¹⁰, S Lau¹¹, M Wechsler^{12

13}, X Bertels^{3

14}, G Liva¹⁵, M Doulaptsi¹⁵, E Prokopakis¹⁵, P W Hellings^{5

16

17}

Affiliations

¹ Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
² Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, Madrid, Spain.
³ The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.
⁴ Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
⁵ Department of Otorhinolarynogology and Head/Neck Surgery, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
⁶ Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
⁷ Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
⁸ Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
⁹ Division of Immunity and Infection, University College, London, United Kingdom.
¹⁰ Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
¹¹ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States.
¹³ Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, United States.
¹⁴ Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands.
¹⁵ Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece.
¹⁶ KU Leuven Department of Microbiology and Immunology, Allergy and Clinical Immunology Research Unit, Leuven, Belgium.
¹⁷ Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.

Abstract

The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.

Keywords: EUFOREA; asthma; biologics; rhinosinusitis; training course; type 2 inflammation.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The European Biologic Training Course for Type 2 Inflammation was organized in Brussels in March 2024 with support of corporate partners of EUFOREA Sanofi Regeneron and GSK. The event received support from Sanofi Regeneron and GSK for the event but not for publishing fee's.